Rising Viral Infections Fueling Advancements In The Hepatitis C Market: Transformative Forces Shaping the Hepatitis C Market Landscape in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Hepatitis C Industry Market Size Be by 2025?
The market encompassing hepatitis C has experienced swift expansion lately, projected to increase from a valuation of $67.17 billion in 2024 to $75.72 billion by 2025, reflecting a compound annual growth rate of 12.7%; this upswing during the past period has been fueled by factors such as established blood transfusion protocols, the prevalence of injection drug use, the former scarcity of therapeutic choices, and the introduction of direct-acting antiviral agents.

What's the Long-Term Growth Forecast for the Hepatitis C Market Size Through 2029?
The financial scope of the hepatitis C market is projected for substantial expansion over coming years, reaching a valuation of $132.21 billion by 2029, propelled by a compound annual growth rate (CAGR) of 15.0%. This anticipated surge in growth throughout the forecasting window is directly linked to worldwide initiatives aiming for eradication, enhancements in diagnostic capabilities and population screening, escalating expenditures in healthcare, the incorporation of remote medical services, and the advent of novel combination therapies. Key shifts expected to shape the market during this timeframe encompass greater availability and lower costs for therapeutic interventions, concentrated attention on populations at elevated risk, enhancements in how medications are formulated, increased inter-organizational cooperation and alliances, and the wider adoption of virtual care and digital platforms.

View the full report here:
https://www.thebusinessresearchcompany.com/report/hepatitis-c-global-market-report

What Are the Key Growth Drivers Fueling the Hepatitis C Market Expansion?
The escalating incidence of viral illnesses is anticipated to be the primary catalyst for the expansion of the hepatitis C market moving ahead. Viral infections, which are those triggered by a virus invading the body, are directly addressed by hepatitis C therapies, as these treatments work to eliminate the viral presence and subsequently rebuild the patient's immune defense mechanisms following the removal of the virus. To illustrate this trend, data released in August 2024 by the Centers for Disease Control and Prevention, a key health organization in the United States, showed a broad increase in the prevalence of Parvovirus B19, a type of seasonal respiratory viral illness, across every demographic bracket, climbing from a 3% rate observed between 2022 and 2024 to reach 10% by June 2024; notably, the sharpest escalation in prevalence was evident among youngsters between five and nine years old, where their rate surged dramatically from 15% during the 2022-2024 period to an impressive 40% as of June 2024. Moreover, the quantity of composite samples testing positive for Parvovirus B19 DNA experienced a substantial climb, moving from just 1.5% in December 2023 up to 19.9% in June 2024, clearly indicating that the surge in viral infections is furnishing substantial impetus to the growth trajectory of the hepatitis C market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12582&type=smp

What Are the Key Trends Driving Hepatitis C Market Growth?
Advancements in diagnostic technologies for hepatitis C are emerging as a major trend in the hepatitis C market. Leading companies in this market are embracing innovative technologies to maintain their competitive edge. For example, in July 2022, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical and diagnostics company, introduced the Elecsys HCV Duo immunoassay in countries recognizing the CE Mark. This immunoassay enables the simultaneous and independent detection of hepatitis C virus (HCV) antigen and antibody status from a single human plasma or serum sample. It assists in identifying patients who are recovering or showing signs of chronic infection, which could potentially progress to conditions such as liver cancer or other early-stage liver diseases.

How Is the Hepatitis C Market Segmented?
The hepatitis cmarket covered in this report is segmented -

1) By Type: Chronic Hepatitis C; Acute Hepatitis C; Other Types
2) By Treatment: Antiviral Drugs; Vaccine; Immune Modulator Drugs; Surgery; Other Treatments
3) By Diagnosis: Liver Biopsy; Blood Tests; Imaging Tests; Other Diagnosis
4) By Distribution Channel: Hospital And Retail Pharmacies; Online Pharmacies
5) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers; Diagnostic Laboratories; Research Institutes; Home Care Settings

Subsegments:
1) By Chronic Hepatitis C: Genotype 1; Genotype 2; Genotype 3; Genotype 4; Genotype 5; Genotype 6
2) By Acute Hepatitis C: Symptomatic; Asymptomatic
3) By Other Types: Mixed Infections; Superinfection

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12582&type=smp

Which Companies Are Leading the Charge in Hepatitis C Market Innovation?
Major companies operating in the hepatitis C market include Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffman La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Sumitomo Corporation, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH., Amgen Inc., Toray Industries Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Aurobindo Pharma Ltd., Cipla Ltd., Lupin Limited, Cadila Healthcare Ltd., Biocon Limited

Which Regions Are Leading the Global Hepatitis C Market in Revenue?
North America was the largest region in the hepatitis C market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis C market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12582

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.